Fierce Biotech
Gilead pays $3.1B upfront for Tubulis to bolster oncology ADC pipeline
Gilead has struck a deal to buy Germany-based Tubulis for $3.15 billion upfront and up to $1.85 billion in milestones, securing an antibody-drug conjugate (ADC) candidate that is racing t | Gilead has struck a deal to buy Tubulis for $3.15 billion upfront and up to $1.85 billion in milestones, secu…
